Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer

Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dismal, mostly due to disease progression and toxicity related to the treatments. One area of...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Prabhsimranjot, Toom, Sudhamshi, Huang, Yiwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427576/
https://www.ncbi.nlm.nih.gov/pubmed/28494772
http://dx.doi.org/10.1186/s13045-017-0473-4
_version_ 1783235657149186048
author Singh, Prabhsimranjot
Toom, Sudhamshi
Huang, Yiwu
author_facet Singh, Prabhsimranjot
Toom, Sudhamshi
Huang, Yiwu
author_sort Singh, Prabhsimranjot
collection PubMed
description Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dismal, mostly due to disease progression and toxicity related to the treatments. One area of active development is looking for ideal monoclonal antibodies (IMAB) specific to the proteins only on the tumor and hence avoiding unnecessary side effects. Claudin proteins with isoform 2 are one such protein, specific for several cancers, particularly gastric cancer and its metastases, leading to the development of anti-claudin 18.2 specific antibody, claudiximab. This review will highlight the latest development of claudiximab as first in class IMAB for the treatment of gastric cancer.
format Online
Article
Text
id pubmed-5427576
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54275762017-05-15 Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer Singh, Prabhsimranjot Toom, Sudhamshi Huang, Yiwu J Hematol Oncol Review Targeted therapy and immunotherapy have revolutionized treatment of various cancers in the past decade. Despite targeted therapy with trastuzumab in Her2-positive gastric cancer patients, survival has been dismal, mostly due to disease progression and toxicity related to the treatments. One area of active development is looking for ideal monoclonal antibodies (IMAB) specific to the proteins only on the tumor and hence avoiding unnecessary side effects. Claudin proteins with isoform 2 are one such protein, specific for several cancers, particularly gastric cancer and its metastases, leading to the development of anti-claudin 18.2 specific antibody, claudiximab. This review will highlight the latest development of claudiximab as first in class IMAB for the treatment of gastric cancer. BioMed Central 2017-05-12 /pmc/articles/PMC5427576/ /pubmed/28494772 http://dx.doi.org/10.1186/s13045-017-0473-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Singh, Prabhsimranjot
Toom, Sudhamshi
Huang, Yiwu
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
title Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
title_full Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
title_fullStr Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
title_full_unstemmed Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
title_short Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
title_sort anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427576/
https://www.ncbi.nlm.nih.gov/pubmed/28494772
http://dx.doi.org/10.1186/s13045-017-0473-4
work_keys_str_mv AT singhprabhsimranjot anticlaudin182antibodyasnewtargetedtherapyforadvancedgastriccancer
AT toomsudhamshi anticlaudin182antibodyasnewtargetedtherapyforadvancedgastriccancer
AT huangyiwu anticlaudin182antibodyasnewtargetedtherapyforadvancedgastriccancer

Ejemplares similares